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BACKGROUND: Assessment of left ventricular (LV) filling pressure is 
among the important components of a comprehensive echocardiographic 
report. Previous studies noted wide limits of agreement using 2009 
American Society of Echocardiography/European Association of 
Echocardiography guidelines, but reproducibility of 2016 guidelines 
update in estimating LV filling pressure is unknown.
METHODS: Echocardiographic and hemodynamic data were obtained 
from 50 patients undergoing cardiac catheterization for clinical 
indications. Clinical and echocardiographic findings but not invasive 
hemodynamics were provided to 4 groups of observers, including 
experienced echocardiographers and cardiology fellows. Invasively 
acquired LV filling pressure was the gold standard.
RESULTS: In group I of 8 experienced echocardiographers from the 
guidelines writing committee, sensitivity for elevated LV filling pressure 
was 92% for all observers, and specificity was 93±6%. Fleiss κ-value for 
the agreement in group I was 0.80. In group II of 4 fellows in training, 
sensitivity was 91±2%, and specificity was 95±2%. Fleiss κ-value 
for the agreement in group II was 0.94. In group III of 9 experienced 
echocardiographers who had not participated in drafting the guidelines, 
sensitivity was 88±5%, and specificity was 91±7%. Fleiss κ-value for the 
agreement in group III was 0.76. In group IV of 7 other fellows, sensitivity 
was 91±3%, and specificity was 92±5%. Fleiss κ-value for the agreement 
in group IV was 0.89.
CONCLUSIONS: There is a good level of agreement and accuracy 
in the estimation of LV filling pressure using the American Society of 
Echocardiography/European Association of Cardiovascular Imaging 2016 
recommendations update, irrespective of the experience level of the 
observer.
© 2019 American Heart Association, Inc.
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Elevated left ventricular (LV) filling pressure is one of the important reasons behind shortness of breath in patients with heart failure. The diagno-
sis is most conveniently established by echocardiogra-
phy. ASE (American Society of Echocardiography) and 
European Association of Echocardiography published 
the first set of guidelines about echocardiographic e-
valuation of LV diastolic function in 2009.1 In these 
guidelines, the writing group recommended consider-
ation of several measurements but allowed for each 
reader to judge the hierarchal importance of individ-
ual variables based on the clinical setting, as well as 
the technical and the pathophysiologic limitations and 
applications. When the 2009 guidelines were tested 
among a group of senior echocardiographers, 1 study 
reported wide interobserver variability, which was at-
tributed, in part, to the inclusion of numerous mea-
surements and the lack of clear recommendation on 
the number of abnormal variables needed to establish 
the diagnosis and their hierarchy.2 In the latter study, 
the investigators used imaging data from 20 patients 
only and did not compare the accuracy of the assess-
ment by different observers against invasive LV filling 
pressure as the gold standard.2 More recently in 2016, 
ASE and EACVI (European Association of Cardiovascu-
lar Imaging) updated LV diastolic function evaluation 
guidelines.3 To our knowledge, there are no data vali-
dating the reproducibility and accuracy of applying the 
most recent guidelines by different observers with var-
iable experience, which is important because the ulti-
mate utility depends on the correct application of the 
guidelines. Thus, we sought to address this question in 
a sample of 50 patients who were randomly selected 
from a study group undergoing echocardiographic im-
aging and cardiac catheterization aimed at looking at 
the accuracy of the 2016 ASE/EACVI updated guide-
lines for estimating LV filling pressure.
METHODS
The data and study material will not be made available in 
public to other researchers. Echocardiographic and hemody-
namic data were obtained from 50 patients who underwent 
cardiac catheterization for clinical indications. The study was 
approved by institutional review board, and patients provided 
written informed consent. The only exclusions were the pres-
ence of mitral valve stenosis, mitral valve repair, prosthetic mi-
tral valves, heart transplants, and complex congenital heart 
disease. In each of these diseases, there are limitations to 
several of the echocardiographic parameters that are used to 
draw conclusions about LV filling pressure and hence the ex-
clusion of patients with these findings. Patients were selected 
at random provided they did not meet the exclusion criteria. 
The presence of a complete data set was not a requisite for 
inclusion because the goal was looking at the day-to-day ap-
plication of the 2016 ASE/EACVI guideline update, including 
feasibility and not only accuracy. Echocardiography was per-
formed either during or immediately post-cardiac catheteriza-
tion and without intervening clinical change or administration 
of medications.
Echocardiographic Studies and Cardiac 
Catheterization
Patients were imaged, and measurements were performed 
according to standard guidelines.3,4 Measurements included 
biplane LV volumes and ejection fraction (EF), biplane left 
atrium (LA) maximum volume index, mitral inflow veloci-
ties (early diastolic velocity or E and late diastolic velocity 
or A, and E/A ratio), tissue Doppler mitral annulus veloci-
ties (septal, lateral, average e′ velocity, and E/e′ ratio) by 
pulse-wave Doppler, peak tricuspid regurgitation velocity 
from multiple windows, and when satisfactorily recorded, 
pulmonary vein velocities. Severity of mitral regurgitation 
was determined per guideline criteria.5 Echocardiographic 
measurements, heart rate, blood pressure, and clinical find-
ings were communicated to the reviewers who were blinded 
to patient identity. The consideration of clinical status is in 
keeping with the 2016 update recommendations, which 
emphasize the need to consider clinical status as the first 
step in the application of the guidelines.3 The findings simu-
late the day-to-day practice in a busy laboratory because not 
all signals were available, and several patients had merging 
of mitral E and A velocities, were in a paced rhythm, or atrial 
fibrillation.
LV filling pressure was mean wedge pressure in 34 patients 
obtained by right heart catheterization and LV pre-A pres-
sure in 16 patients obtained during left heart catheterization. 
Mean wedge pressure (pulmonary capillary wedge pressure) 
and LV pre-A pressure are closely related,6 and thus LV pre-A 
pressure was used as a surrogate for mean wedge pressure, 
which is also consistent with recommendations of the 2016 
guidelines.3 An LV filling pressure >12 mm Hg was considered 
elevated based on recommendations for diagnosis of heart 
failure with normal LV EF.7
CLINICAL PERSPECTIVE
Assessment of left ventricular diastolic function is 
important for determination of underlying cause 
of dyspnea. Echocardiography is a readily avail-
able, versatile technique that can accomplish this 
objective. American Society of Echocardiography/
European Association of Cardiovascular Imaging 
guidelines for the evaluation of left ventricular 
diastolic function have good accuracy and good 
agreement when variability is tested among 
observers with different levels of background and 
experience. The routine assessment and reporting 
of left ventricular diastolic function and filling pres-
sure is, therefore, encouraged. Additional studies 
are of value in looking at more novel indices of 
cardiac function, their variability, and what incre-
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Analysis of Interobserver Variability
The main objective was to look at variability in apply-
ing the guidelines and not in performing actual measure-
ments. Thus, we used a similar design to a previous study2 
addressing this objective, which did not evaluate variability 
in measurements performed by different observers. The 
tabulated data of each patient, including clinical and echo-
cardiographic findings but not invasive hemodynamics, were 
provided to 4 groups of observers. In the application of the 
guidelines, the different observers took notice of clinical 
status and 2-dimensional (2D) and Doppler findings as rec-
ommended in the guidelines.3 In patients with normal LV EF, 
the presence of clinical diagnoses associated with diastolic 
dysfunction and heart failure with preserved EF was con-
sidered as hypertensive cardiovascular disease (hypertension 
plus pathological LV hypertrophy based on LV mass index or 
hypertension plus LA enlargement based on LA maximum 
volume index), diabetes mellitus, chronic kidney disease, 
and coronary artery disease with segmental dysfunction. In 
many laboratories, these data are routinely obtained and 
are available to the interpreting physicians being readily ac-
cessible from electronic health records. After consideration 
of clinical and 2D data, patients were determined to have 
one of the following: myocardial disease with normal EF, de-
pressed EF, or none. If the answer was affirmative (depressed 
EF or myocardial disease with normal EF), then estimation of 
LV filling pressure proceeded as recommended in the specific 
algorithm in the 2016 guidelines (see Figure 8B in the guide-
lines by Nagueh et al3). On the contrary, if there was no evi-
dence of myocardial disease in patients with normal EF, then 
the 4 variables (mitral annulus velocities, average E/e′ ratio, 
LA maximum volume index, and peak tricuspid regurgita-
tion velocity by continuous wave Doppler from multiple win-
dows) were evaluated to arrive at a conclusion of whether 
diastolic dysfunction was present or absent (see Figure 8A in 
the guidelines by Nagueh et al3). If 2 of 3 or 3 of 4 signals 
were abnormal, diastolic dysfunction was deemed present 
and the exercise of LV filling pressure estimation followed 
(see Figure 8B in the guidelines by Nagueh et al3).
We sought to include investigators from the diastolic 
guidelines writing group members, as well as other inves-
tigators who did not participate in drafting the guidelines. 
This would allow for comparison between investigators 
who are the most familiar with the guidelines and other 
investigators who would be applying them the way they in-
terpret the guidelines. In addition, we wanted to compare 
the performance of experts and trainees. Thus, 1 group 
was comprised of 8 experienced echocardiographers who 
were members of the 2016 diastolic function guidelines 
writing group. They included physicians from Belgium, 
Italy, Norway, Romania, Sweden, and the United States. 
The second group was comprised of 4 fellows undergo-
ing training in cardiology from 2 institutions in the United 
States who had members in the guidelines writing group 
(M.A.C.-p., K.C.E.t., S.C.H., J.G.). The third group was 
comprised of echocardiographers who were not members 
of the writing group. They included physicians from France, 
Italy, the Netherlands, and the United States. The fourth 
group was comprised of 7 fellows from the same institu-
tions of group 3 observers (A.B., A.H., G.D., R.E., R.Z.M., 
M.P., S.R.S.).
The trainees participating in the analysis were designated 
by the lab head, but there was no a priori testing of their 
accuracy or agreement with the experienced echocardiogra-
pher. The invasively acquired LV filling pressure was the gold 
standard against which the accuracy of the different observ-
ers was tested.
Statistical Analysis
Sensitivity and specificity of the different observers in 
detecting elevated LV filling pressure were calculated, and 
their mean and SD values, as well as median and range 
were obtained. Agreement between the different mem-
bers of each group of observers was assessed by Fleiss 
κ-statistics, and the 95% CIs are presented in the results. 
The sample size was based on an expected margin of error 
at 12% to 15% of physicians agreeing with a statement 
pertaining to status of LV filling pressure. At a sample size 
of 50, if 70% of reviewers agree to the statement, then be-
tween 57% and 83% (expected margin of error is ≈13%) 
of all physicians will agree to the same statement. All anal-
yses were performed with STATA, version 14 (Stata Corp LP, 
College Station, TX). Sherif F. Nagueh, MD, had full access 
to all the data in the study and takes responsibility for its 
integrity and the data analysis.
RESULTS
The diagnoses, heart rate and rhythm, presence 
and severity of mitral regurgitation, and 2D find-
ings for each patient are shown in Tables 1 and 2. 
All patients were in sinus rhythm except 4 patients 
with a paced rhythm and 1 patient in atrial fibrilla-
tion. There were 22 patients with EF <50%. None 
of the patients had more than mild mitral annular 
calcification. Table 2 presents the echocardiographic 
measurements and invasive LV filling pressure. Fig-
ures 1 and 2 show examples from 2 patients. Mov-
ies I through III in the Data Supplement show the 
2D findings from the patient with Doppler data in 
Figure 2. Mitral inflow (E/A ratio and peak E veloc-
ity) was sufficient to estimate LV filling pressure in 
14 patients, and other parameters were needed in 
the remaining patients. Two patients had indeter-
minate LV filling pressure by the 2016 ASE/EACVI 
guidelines.
Agreement Between Group I (Guidelines 
Writing Group Members) Experienced 
Observers in the Estimation of LV Filling 
Pressure
Sensitivity for elevated LV filling pressure was identical 
for all 8 experienced observers at 92% using the inva-
sive measurement as the gold standard (Table 3). Spec-
ificity was 93±6% (range, 84%–100%). Fleiss κ-value 
for the agreement between the different observers was 
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Agreement Between Group II (Fellows in 
Training) in the Estimation of LV Filling 
Pressure
Sensitivity for elevated LV filling pressure was 91±2% and 
had a range between 88% and 92%, using the invasive 
measurement as the gold standard. Likewise, specificity 
was excellent at 95±2% and had a range between 92% 
and 96% (Table 3). Fleiss κ-value for the agreement be-
tween the 4 trainees was 0.94 (95% CI, 0.88–1.00).
Agreement Between Group III 
Experienced Observers (Not Members 
of the Guidelines Writing Group) in the 
Estimation of LV Filling Pressure
Sensitivity for elevated LV filling pressure was 88±5% 
and had a range between 80% and 92%, using the 
invasive measurement as the gold standard (Table 3). 
Specificity was 91±7% (range, 80–100). Fleiss κ-value 
for the agreement was 0.76 (95% CI, 0.68–0.84).
Agreement Between Group IV (Fellows 
in Training) in the Estimation of LV Filling 
Pressure
Sensitivity for elevated LV filling pressure was 91±3% 
and had a range between 84% and 92%, using the 
invasive measurement as the gold standard. Specific-
ity was 92±5%, and had a range between 88% and 
100% (Table 3). Fleiss κ-value for the agreement was 
0.89 (95% CI, 0.83–0.96).
Agreement in Grading LV Diastolic 
Dysfunction
Good agreement was present in grading LV diastolic 
dysfunction. Fleiss κ-value for the agreement between 
Table 1. Clinical Diagnosis of the 50 Patients
Patient No. Clinical Diagnosis Patient No. Clinical Diagnosis
1 DCM on milrinone 26 CAD, PVD, CKD, AS, CABG, on 
dobutamine
2 CAD, CKD, DM 27 HTN CVD, PVD
3 DCM on IV Lasix 28 CAD, HTN CVD
4 HFpEF, HTN CVD, CKD 29 HFpEF, HTN CVD
5 CAD, CABG, HTN 30 HTN, CAD, DM, HFrEF
6 HTN CVD 31 HTN CVD, CAD, CABG, COPD
7 HTN CVD, CKD 32 HFpEF, HTN CVD
8 Peripartum cardiomyopathy 33 Dilated cardiomyopathy
9 Nonischemic cardiomyopathy 34 CAD
10 HTN CVD, CKD 35 CAD
11 COPD 36 CAD
12 PCI to proximal LAD 37 HTN, pulmonary disease
13 PCI to proximal LAD 38 HTN, paroxysmal atrial fibrillation
14 PCI to proximal and mid-LAD 39 COPD
15 HFpEF, HTN CVD 40 Dilated cardiomyopathy
16 HFpEF, HTN CVD 41 HFrEF
17 CAD, ischemic cardiomyopathy 42 HTN CVD
18 Severe AS, CAD, CKD 43 HTN CVD
19 HFpEF, HTN CVD, CAD, DM 44 Dilated cardiomyopathy
20 HFpEF, HTN CVD 45 Dilated cardiomyopathy
21 CAD 46 HTN CVD, CKD
22 HFpEF, HTN CVD 47 Dilated cardiomyopathy
23 HFrEF 48 CAD, persistent atrial fibrillation
24 CAD, acute MI, HTN 49 Precapillary pulmonary HTN
25 CAD, CABG, DM, HTN, CKD 50 CAD, severe tricuspid regurgitation
HTN CVD was diagnosed in the presence of HTN and LA enlargement or LV hypertrophy as determined by LV 
mass index. AS indicates aortic stenosis; CABG, coronary artery bypass graft surgery; CAD, coronary artery disease; 
CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DCM, dilated cardiomyopathy; DM, 
diabetes mellitus; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection 
fraction; HTN, hypertension; HTN CVD, hypertensive cardiovascular disease; IV, intravenous; LA, left atrium; LAD, 
left anterior descending coronary artery; LV, left ventricle; MI, myocardial infarction; PCI, percutaneous coronary 




 http://ahajournals.org by on November 13, 2019
Circ Cardiovasc Imaging. 2019;12:e008122. DOI: 10.1161/CIRCIMAGING.118.008122 January 2019 5
Nagueh et al; Variability in Estimating LV Filling Pressure
the 8 observers in group I was 0.82 (95% CI, 0.74–
0.91). Fleiss κ-value for the agreement between the 
4 trainees in group II was 0.96 (95% CI, 0.91–1.00). 
Fleiss κ-value for the agreement between the observers 
in group III was 0.75 (95% CI, 0.66–0.84). Fleiss κ-value 
for the agreement between the observers in group IV 
was 0.80 (95% CI, 0.72–0.88).
DISCUSSION
To our knowledge, this is the first report looking at the 
interobserver variability in applying ASE/EACVI 2016 
guidelines for the evaluation of LV filling pressure. Sen-
sitivity and specificity for detecting elevated LV filling 
pressure were good irrespective of the experience level.
Sources of Variability in Evaluating LV 
Diastolic Function
There are several reasons that can lead to increased 
variability in the assessment of LV diastolic function. 
These include technical factors, as well as analysis fac-
tors. Although technical aspects were not evaluated in 
this study, suboptimal signals if acquired and used to 
draw inferences about LV filling pressure can lead to 
erroneous conclusions not only because of their spu-
rious values but also because of large variation in the 
Table 2. Summary Statistics of Clinical, 2-Dimensional, and Doppler 
Findings in the 50 Patients
Parameter  
Age, y 58±13
Heart rate (per min) 73±16
Rhythm Sinus in 42 patients, paced rhythm in 4, sinus 
tachycardia in 3, and atrial fibrillation in 1 patient
MR severity No MR in 19, trivial MR in 6, mild MR in 13, 
moderate MR in 10, and severe MR in 2 patients
LV EF, % 51±19.7
LA maximum volume 
index, mL/m2
44±21
Peak E velocity, cm/s 84.6±28.5
E/A ratio 1.6±1.1
Peak TR velocity, m/s 2.8±0.6
Average E/e′ ratio 13.5±6.7
Invasive LV filling 
pressure, mm Hg
16±10
A indicates peak mitral late diastolic velocity; E, peak early diastolic velocity; 
e′, early diastolic velocity by tissue Doppler; EF, ejection fraction; LV, left 
ventricle; MR, mitral regurgitation; and TR, tricuspid regurgitation.
Figure 1. Mitral inflow (upper left), lateral tissue Doppler (TD) velocities (upper right), tricuspid regurgitation velocity by continuous-wave Doppler 
(lower left), and zoomed view for the left atrium in apical 4-chamber view (lower right) from a patient with hyperdynamic LVEF.  
Mitral inflow shows impaired relaxation pattern with mitral peak early diastolic velocity (E)/peak mitral late diastolic velocity (A) ratio <0.8 and peak E velocity <50 
cm/s. Lateral mitral annulus TD mitral annulus early diastolic velocity by TD (e′) velocity is reduced at 6 cm/s, with average E/e′ ratio at 9.5. Left atrium maximum 
volume index was normal, and peak tricuspid regurgitation velocity was rather incomplete. LV filling pressure was normal at 8 mm Hg. a′ indicates mitral annulus 
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measurement of suboptimal signals by different observ-
ers. For example, when mitral annulus velocities are ac-
quired with suboptimal gain and filter settings, there is 
often difficulty in determining the onset of the e′ veloc-
ity and its peak value. A foreshortened LA will result in 
underestimation of the true LA maximum volume, no 
matter how carefully the LA endocardium is traced. In 
each of the above examples, the observer should not 
rely on the suboptimal signal in drawing conclusions 
about LV filling pressure.
Likewise, satisfactory signals, if incorrectly measured, 
can lead to wrong conclusions. Training plays an im-
portant role in obtaining correct measurements and 
increasing interobserver agreement for the assessment 
of LV diastolic function as has been recently shown.8
On the analysis side, incorrect application of the 
guidelines can be a challenging hurdle to contend with 
in trying to improve interobserver agreement. In that 
regard, the 2016 guidelines are explicit in recommend-
ing consideration of clinical findings, 2D data, as well 
as Doppler signals in trying to reach conclusions about 
LV diastolic function. The appropriate consideration of 
the presence of myocardial disease, which involves clin-
ical assessment, as well as 2D and Doppler findings, 
Figure 2. Mitral inflow (upper left), septal tissue Doppler (TD) velocities (upper right), lateral TD velocities (lower left), and peak tricuspid regurgi-
tation (TR) velocity (lower right) from an 81-y-old woman with history of hypertension.  
LV size and function are normal with preserved ejection fraction and normal LA volume (Movies I through III in the Data Supplement). Peak tricuspid regurgitation 
velocity is 2 m/s, mitral peak early diastolic velocity (E)/peak mitral late diastolic velocity (A) ratio is 1.3, septal and lateral annular velocities are reduced. Average E/
mitral annulus early diastolic velocity by TD (e′) ratio is >14. LV global longitudinal strain was normal at −21.1%. Accordingly, there is no evidence of myocardial 
disease, and one has to rely on the 4 variables (annular e′ velocities, average E/e′ ratio, LA maximum volume index, and peak tricuspid regurgitation velocity). Be-
cause only 2 of the 4 variables are abnormal (e′ velocities and average E/e′ ratio), LV diastolic function is indeterminate per the 2016 guidelines. a′ indicates mitral 
annulus late diastolic velocity by TD.















I 92±0.00 92 92–92 93±6 94 84–100
II 91±2 92 88–92 95±2 96 92–96
III 88±5 88 80–92 91±7 92 80–100
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reduces the number of cases with indeterminate LV 
filing pressure. Furthermore, there is a clear hierarchy 
with respect to the sequence of signals considered and 
the number of abnormal findings that should be pre-
sent before concluding that LV filling pressure is ele-
vated. Accordingly, the overall agreement we noticed in 
our study is much higher than that reported previously.2 
Importantly, the satisfactory agreement was noticed 
for experienced observers irrespective of whether they 
were members of the guidelines writing group or not, 
as well as cardiology fellows in training.
Implications for Clinical Application of 
the 2016 ASE/EACVI Guidelines
The ultimate goal of any set of guidelines is to improve 
patient care, thus potentially contributing to better out-
comes. The 2016 ASE/EACVI diastolic function guide-
lines render the assessment of LV filling pressure more 
consistent among different levels of observers as shown 
in this study. Further, they have good accuracy in iden-
tifying patients with elevated LV filling pressure. As a 
result of higher reproducibility and high accuracy, the 
guidelines are useful in drawing the attention of refer-
ring clinicians to the status of LV filling pressure, which 
in turn can help confirm the diagnosis of heart failure, 
as well as inform fluid management decisions.
Limitations
The study design did not evaluate the interobserver var-
iability in measuring 2D and Doppler parameters. We 
did not seek to assess measurement variability because 
the main objective of our study was to evaluate the 
agreement of different observers in reaching the cor-
rect conclusion about LV filling pressure when applying 
the 2016 guidelines given the wide variability reported 
with the application of the 2009 guidelines.2 In that re-
gard, the current study design with confined analysis to 
guideline application as opposed to measurement varia-
bility is similar to a previous study looking at agreement 
between different observers in evaluating LV diastolic 
function.2 Although there were 50 patients, there were 
1400 assessments in total by the observers. One of the 
reasons behind the results observed is the availability of 
a satisfactory tricuspid regurgitation jet in 34 of the 50 
patients (68%), and it is possible that lower and higher 
feasibility rates can affect the results. Notwithstanding, 
tricuspid regurgitation is one of the important signals 
that is endorsed in several guideline recommendations 
for the estimation of pulmonary artery systolic pressure 
and should be routinely acquired. Patients who undergo 
cardiac catheterization are more likely to have cardiac 
disease and diastolic dysfunction. However, if one is to 
test the accuracy of the guidelines, the gold standard 
of invasive LV filling pressure is needed. The accuracy 
of the guidelines in general, as a separate issue aside 
from variability, is likely lower in populations with lower 
prevalence of cardiovascular disease and in asympto-
matic subjects. With respect to patients not undergoing 
cardiac catheterization, outcome events as incidence of 
heart failure and cardiac mortality may be used to gain 
insight into the ability of the guidelines to predict out-
comes.9 There were few patients with a paced rhythm 
or atrial fibrillation, and additional studies are needed to 
evaluate the variability of the application of the guide-
lines in patients with these rhythms.
Conclusions
There is a good interobserver agreement in the evalua-
tion of LV filling pressure using the ASE/EACVI 2016 up-
date irrespective of the experience level of the observer. 
This conclusion is the most applicable when satisfactory 
quality signals are acquired and carefully measured.
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